Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 948-950

  Shen, Li ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Foxp3; HDAC inhibitors; Immunotherapy; Regulatory T cells; STAT3

Indexed keywords

ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; STAT3 PROTEIN; TRICHOSTATIN A;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; DRUG CLASSIFICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FOXP3 GENE; GENE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE;

EID: 84886943464     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20306     Document Type: Article

References (10)

1. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008; 14:1032-40; PMID:18281535; http://dx.doi.org/10.1158/1078-0432.CCR-07-2056.
2. + immu-noregulatory T cells hinder tumor immunotherapy? J Immunother 2002; 25:202-6; PMID:12000861; http://dx.doi.org/10.1097/00002371-200205000-00002.
3. + regulatory T cells in cancer patients. Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood-2005-06-2399.
4. Colombo M P, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7:880-7; PMID:17957190; http://dx.doi.org/10.1038/nrc2250.
5. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 2012; 7:30815; PMID:22303460; http://dx.doi.org/10.1371/journal.pone.0030815.
6. Tao R, de Zoeten E F, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-307; PMID:17922010; http://dx.doi.org/10.1038/nm1652.
7. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010; 115:965-74; PMID:19996091; http://dx.doi.org/10.1182/blood-2009-02-207118.
8. Huber M, Steinwald V, Guralnik A, Brüstle A, Kleemann P, Rosenplänter C, et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 2008; 20:223-34; PMID:18156621; http://dx.doi.org/10.1093/intimm/dxm139.
9. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307:269-73; PMID:15653507; http://dx.doi.org/10.1126/sci-ence.1105166.
10. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009; 280:233-41; PMID:19344997; http://dx.doi.org/10.1016/j.canlet.2009.02.019.